ProciseDx Announces Acquisition by Biosynex S.A. to Transform Biologics Therapeutic Drug Monitoring in the US Peter WestlakeJune 13, 2023
ProciseDx announces FDA Clearance of ProciseDx instrument and C Reactive Protein (CRP) assay Peter WestlakeNovember 10, 2022
ProciseDx Announces $13 Million Convertible Note Financing and Strong International Growth Guest UserJuly 16, 2021
ProciseDx™ Secures $10.5 Million Series A Financing Round Led by Biosynex, Forms an Independent Point-Of-Care Diagnostic Company Elizabeth JenningsJuly 21, 2020
ProciseDx™ Files 510k and Prepares for EU launch of Novel Point of Care Technology Guest UserMay 14, 2020
ProciseDx™ Announces CE Mark for Point of Care Inflammatory Marker Assay Elizabeth JenningsJanuary 10, 2020
ProciseDx™ Announces CE Mark for Point of Care Platform and Plans for Additional Financing in Q1 2020 Elizabeth JenningsSeptember 25, 2019
